Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA3 | P34903 | 17/20 | 0.81 |
| ▸ | GABRG2 | P18507 | 15/20 | 0.81 |
| ▸ | GABRB3 | P28472 | 15/20 | 0.81 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.79 |
| ▸ | GABRA1 | P14867 | 9/20 | 0.75 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.75 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.59 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.59 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13061667 | 0.90 | GABRA3 (1.00) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL29691961 | 0.89 | GABRA3 (0.84) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL19368515 | 0.89 | GABRA3 (0.84) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL13061810 | 0.88 | GABRA3 (0.80) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL13835722 | 0.88 | GABRA3 (0.81) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL8363087 | 0.88 | GABRA3 (1.00) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL16638525 | 0.88 | GABRG2 (0.74) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL13061808 | 0.86 | GABRA3 (0.82) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL29712107 | 0.86 | GABRG2 (1.00) | GABRA3GABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL639547 | 0.86 | GABRG2 (1.00) | GABRA3GABRG2GABRB3GABRA2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9597342-B2 | GABAergic receptor subtype selective ligands and their uses | UWM RESEARCH FOUNDATION, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9597342-B2 | GABAergic receptor subtype selective ligands and their uses | UWM RESEARCH FOUNDATION, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150258128-A1 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES | UWM RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150258128-A1 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES | UWM RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
| US-9006233-B2 | Gabaergic receptor subtype selective ligands and their uses | UWM RESEARCH FOUNDATION, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006233-B2 | Gabaergic receptor subtype selective ligands and their uses | UWM RESEARCH FOUNDATION, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006233-B2 | Gabaergic receptor subtype selective ligands and their uses | UWM RESEARCH FOUNDATION, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120295892-A1 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES | UWM RESEARCH FOUNDATION, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295892-A1 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES | UWM RESEARCH FOUNDATION, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| US-20100317619-A1 | Selective Agents for Pain Suppression | COOK JAMES | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317619-A1 | Selective Agents for Pain Suppression | CNR2, CNR1, OPRL1 | GABRA3 8/4885GABRG2 25/4885GABRB3 7/4885 |
| US-20150258128-A1 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES | GABRA3, GABRA2, GABRB3 | GABRA3 1/4885GABRG2 10/4885GABRB3 3/4885 |
| US-20120295892-A1 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES | GABRA3, GABRA2, GABRB3 | GABRA3 1/4885GABRG2 10/4885GABRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.